Jingwei Wang

Jingwei Wang

Auto-generated profile, based on publicly available information

Jingwei Wang

Second Department of Orthopedics, Tangshan Gongren Hospital, Tangshan, China

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2005 in Expert Review of Cardiovascular Therapy
Verified
Journal Article
Closed access
XGXiaobing Guo
Xiaobing Guo
HSHarjot K Saini
Harjot K Saini
JWJingwei Wang
Jingwei Wang
SGSuresh K Gupta
Suresh K Gupta
RGRamesh K Goyal
Ramesh K Goyal
NDNaranjan Dhalla
Naranjan Dhalla
Ventricular remodeling subsequent to myocardial infarction (MI) is a complex process and is considered to be a major determinant of the clinical course of congestive heart failure (CHF). Emerging evidence suggests that activation of the renin-angiotensin system (RAS) plays an important role in post-MI ventricular remodeling; however, it is becoming clear that this is one of several neurohumoral systems that are activated in CHF. Blockade of RAS by angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor antagonists attenuates the ventricular dysfunction, but the effects of individual drugs in reducing the morbidity and mortality in CHF patients are variable. Furthermore, there is a difference of opinion as to the time of initiation of therapy with RAS blockers after the onset of MI. Since blockade of RAS partially improves cardiac function, it is suggested that a combination therapy involving RAS blockers (angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor antagonists) and agents that affect other neurohumoral systems may prove useful for improved treatment of CHF. Although activation of RAS has been shown to promote oxidative stress in experimental studies, the use of antioxidant therapy in CHF patients is controversial. Recent experimental studies have shown that ventricular remodeling in CHF is associated with remodeling of subcellular organelles such as sarcolemma, sarcoplasmic reticulum, myofibrils and extracellular matrix in terms of their molecular structure and composition. Since attenuation of remodeling in one and/or more subcellular organelles by different agents may prevent the progression of CHF, it is a challenge to develop specific drugs affecting molecular mechanisms associated with subcellular remodeling for the improved therapy of CHF.

25 December 2018 in Geriatrics & Gerontology International
Verified
Journal Article
Closed access
PDF file
MRMingguang Ren
Mingguang Ren
WLWeidong Liang
Weidong Liang
ZWZhiyu Wu
Zhiyu Wu
HZHongmei Zhao
Hongmei Zhao
JWJingwei Wang
Jingwei Wang